ASHA Learning Pass

Log in and check out the Dashboard to view featured courses.

Filter Courses By
Profession
Setting [clear]
Client Age
Topic Area
Experience
Course Format
SIG [clear]
Instructional Level
Credit(s): PDHs: 1.0, ASHA CEUs*: 0.1
Summary: Ototoxic medications and chemical agents in the workplace can put individuals' hearing and vestibular health at risk for permanent injury. Proactive ototoxicity management (OtoM) strategies aim to minimize exposure, avoid onset of symptoms, provide ongoing monitoring, and manage auditory and vestibular changes as the clinical needs of the patient evolve. During a 2021 American Speech-Language-Hearing Association Special Interest Groups Open House, members of the International Ototoxicity Management Group discussed how best to integrate OtoM into routine clinical practice, what tools to use, and what special considerations need to be understood to best support patients and their families. Here, we have summarized their viewpoints to encourage widespread adoption of improved OtoM services for at-risk individuals. The field of audiology needs to move to a place where we better understand the full extent of ototoxicity and can agree on expanding minimum guidelines that can be implemented more universally to mitigate, detect, and manage the damage from ototoxic exposures. Only recently has our field seen a therapeutic drug that can protect against ototoxicity; however, the population served is restricted only to children receiving treatment for nonmetastatic carcinoma. This is hopefully just the beginning of future therapeutic interventions to come, but, in the meantime, ototoxicity resulting from other medications in different patient populations and chemical agents persists.
Credit(s): PDHs: 1.0, ASHA CEUs*: 0.1
Summary: As a step toward developing an electrophysiologic method for validating the speech feature discrimination benefits of amplification, the article in this SIG 6 activity evaluates the effect of stimulus level and amplification on the acoustic change complex in adults with sensorineural hearing loss.
Credit(s): PDHs: 0.5, ASHA CEUs*: 0.05
Summary: The article in this SIG 6 activity focuses on the audiologic variations seen among patients undergoing the same type of ototoxic drug treatment (cisplatin). Results show a large amount of audiologic outcome variability among the two patients examined, despite similar demographic factors, drug treatments, and types of cancer. Factors relating to ototoxic susceptibility are discussed, and the importance of otoxicity monitoring programs for early detection of audiologic change is highlighted.